Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CSPC Pharmaceutical Group Limited
  6. Summary
    1093   HK1093012172

CSPC PHARMACEUTICAL GROUP LIMITED

(1093)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
9.87 9.54 9.25 9.05 9.08 Last
51941630 39765570 47578210 52999690 47426540 Volume
+0.82% -3.34% -3.04% -2.16% +0.33% Change
Estimated financial data (e)
Sales 2021 33 958 M 4 360 M 4 360 M
Net income 2021 6 768 M 869 M 869 M
Net cash position 2021 12 256 M 1 573 M 1 573 M
P/E ratio 2021 15,4x
Yield 2021 1,80%
Sales 2022 38 834 M 4 986 M 4 986 M
Net income 2022 7 641 M 981 M 981 M
Net cash position 2022 16 394 M 2 105 M 2 105 M
P/E ratio 2022 13,7x
Yield 2022 1,94%
Capitalization 108 B 13 894 M 13 887 M
EV / Sales 2021 2,82x
EV / Sales 2022 2,36x
Nbr of Employees 23 300
Free-Float -
More Financials
Company
CSPC Pharmaceutical Group Ltd. specializes in the development, manufacture and marketing of pharmaceutical products. Net sames by category of products break down as follows: - drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%); - vitamin C (10.1%); - antibiotics (6.2%); - other (5%): including anhydrous and raw caffeine. Net sales are distributed geographically as follows: China... 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Ratings of CSPC Pharmaceutical Group Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CSPC PHARMACEUTICAL GROUP LIMITED
01/18Hong Kong Hang Seng Index Down 0.4% on Wall Street Signals
MT
01/13Chinese Regulators Approve CSPC Pharma's Drug Registration for Generic Hepatocellular C..
MT
01/12Chinese Regulators OK CSPC Pharma's Drug Registration for Peripheral T-Cell Lymphoma Tr..
MT
01/11Chinese Regulators OK CSPC Pharma's Drug Registration for Generic Bone Damage Treatment
MT
01/10Hong Kong Hang Seng Up 1.1% on Property and Tech Gains
MT
01/04Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Announce Approval of IND Appl..
CI
2021CSPC Pharma Wins Nod to Start Tumor Drug's Clinical Trial in China
MT
2021CSPC Pharmaceutical Group Discloses Right-of-use Assets' Values Under Renewed Lease Agr..
MT
2021CSPC Pharmaceutical Group Limited Obtains Approval for SYHX2001
CI
2021CSPC Pharma Doses First Patient in Lymphoma Drug's US Clinical Trial
MT
2021CSPC Pharmaceutical Group Limited Announces First Patient Dosed in the Phase 1/2 Clinic..
CI
2021China’s $1.1 Trillion Healthcare Sector to Grow 9.5% Annually in 10 Years, Nomura..
MT
2021CSPC Pharma's Fungal Infections Treatment Included in China's National Reimbursement Dr..
MT
2021CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,197,376,973 sh..
CI
2021CSPC Pharmaceutical Renews Pharma Supply Deal With CSPC Holdings
MT
More news
News in other languages on CSPC PHARMACEUTICAL GROUP LIMITED
01/18L'indice Hang Seng de Hong Kong en baisse de 0,4 % en raison des signaux de Wall Bourse
01/10Le Hang Seng de Hong Kong progresse de 1,1 % grâce aux gains immobiliers et technologiq..
01/04Alphamab Oncology et CSPC Pharmaceutical Group Co, Ltd. annoncent l'approbation de la d..
2021CSPC Pharmaceutical Group Limited obtient l'approbation du SYHX2001
2021CSPC Pharma administre une dose au premier patient de l'essai clinique américain d'un m..
More news
Analyst Recommendations on CSPC PHARMACEUTICAL GROUP LIMITED
More recommendations
Chart CSPC PHARMACEUTICAL GROUP LIMITED
Duration : Period :
CSPC Pharmaceutical Group Limited Technical Analysis Chart | 1093 | HK1093012172 | MarketScreener
Technical analysis trends CSPC PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 9,08 HKD
Average target price 13,05 HKD
Spread / Average Target 43,7%
EPS Revisions
Managers and Directors
Dong Chen Cai Chairman & Co-Chief Executive Officer
Cui Long Zhang Vice Chairman & Co-Chief Executive Officer
Bo Wang Independent Non-Executive Director
Chuan Chen Independent Non-Executive Director
Chun Kwok Au Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CSPC PHARMACEUTICAL GROUP LIMITED7.20%13 848
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642